Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 5/2021

01-05-2021 | Multiple Sclerosis | COVID-19

Transient monocular visual impairment as an initial symptom of COVID-19 infection in an individual with multiple sclerosis receiving teriflunomide

Authors: Mehmet Fatih Yetkin, Nur Aleyna Yetkin, Merve Akcakoyunlu, Meral Mirza

Published in: Neurological Sciences | Issue 5/2021

Login to get access

Abstract

In December 2019, coronavirus disease 2019 (COVID-19) emerged in Wuhan and rapidly spread throughout China. Since the outbreak of the pandemic, in addition to the well-known COVID-19 symptoms, various neurological symptoms have been also described in patients with COVID-19. Here, we report an unusual presentation of COVID-19 infection in a teriflunomide-treated individual with multiple sclerosis (MS) who did not interrupt teriflunomide treatment during the infection. The course of the infection was mild in this case as in other reported teriflunomide-treated individuals with COVID-19. COVID-19’s presentation may be unusual in people with MS (pwMS). It can also be concluded that teriflunomide may be considered a safe disease-modifying treatment option during the pandemic.
Literature
1.
Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y (2020) The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents 55(5):105955CrossRef
2.
Asadi-Pooya AA, Simani L (2020) Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci 413:116832CrossRef
3.
Montalvan V, Lee J, Bueso T, de Toledo J, Rivas K (2020) Neurological manifestations of COVID-19 and other coronavirus infections: a systematic review. Clin Neurol Neurosurg 194:105921CrossRef
4.
Manji H, Carr AS, Brownlee WJ, Lunn MP (2020) Neurology in the time of COVID-19. J Neurol Neurosurg Psychiatry 91(6):568–570CrossRef
5.
Sepehrinezhad A, Shahbazi A, Negah SS (2020) COVID-19 virus may have neuroinvasive potential and cause neurological complications: a perspective review. J Neuro-Oncol 26(3):324–329
6.
Karussis D (2014) The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun 48-49:134–142CrossRef
7.
Maghzi AH et al (2020) COVID-19 in teriflunomide-treated patients with multiple sclerosis. J Neurol:1–7
8.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173CrossRef
9.
Jain A, Rosso M, Santoro JD (2020) Wilhelm Uhthoff and Uhthoff’s phenomenon. Mult Scler 26(13):1790–1796CrossRef
10.
Park K, Tanaka K, Tanaka M (2014) Uhthoff’s phenomenon in multiple sclerosis and neuromyelitis optica. Eur Neurol 72(3–4):153–156CrossRef
11.
Davion JB, Lopes R, Drumez É, Labreuche J, Hadhoum N, Lannoy J, Vermersch P, Pruvo JP, Leclerc X, Zéphir H, Outteryck O (2020) Asymptomatic optic nerve lesions: an underestimated cause of silent retinal atrophy in MS. Neurology 94(23):e2468–e2478CrossRef
12.
Boziki MK, Mentis AA, Shumilina M, Makshakov G, Evdoshenko E, Grigoriadis N (2020) COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination. Brain Sci 10(6):345CrossRef
13.
Kalincik T (2015) Multiple sclerosis relapses: epidemiology, outcomes and management. A systematic review. Neuroepidemiology 44(4):199–214CrossRef
14.
Hamdy SM, Abdel-Naseer M, Shehata HS, Hassan A, Elmazny A, Shalaby NM, Abokrysha NT, Kishk NA, Nada MAF, Ahmed SM, Hegazy MI, Mekkawy D, Mourad HS, Abdelalim A, Berger T (2020) Managing disease-modifying therapies and breakthrough activity in multiple sclerosis patients during the COVID-19 pandemic: toward an optimized approach. Ther Clin Risk Manag 16:651–662CrossRef
15.
Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H (2014) Teriflunomide and its mechanism of action in multiple sclerosis. Drugs 74(6):659–674CrossRef
16.
Comi G, Miller AE, Benamor M, Truffinet P, Poole EM, Freedman MS (2020) Characterizing lymphocyte counts and infection rates with long-term teriflunomide treatment: pooled analysis of clinical trials. Mult Scler 26(9):1083–1092CrossRef
17.
18.
Möhn N et al (2020) Mild COVID-19 symptoms despite treatment with teriflunomide and hi3gh-dose methylprednisolone due to multiple sclerosis relapse. J Neurol 1–3
Metadata
Title
Transient monocular visual impairment as an initial symptom of COVID-19 infection in an individual with multiple sclerosis receiving teriflunomide
Authors
Mehmet Fatih Yetkin
Nur Aleyna Yetkin
Merve Akcakoyunlu
Meral Mirza
Publication date
01-05-2021
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 5/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-021-05097-2

Other articles of this Issue 5/2021

Neurological Sciences 5/2021 Go to the issue

Letter to the Editor

A case of concurrent anti-myelin oligodendrocyte glycoprotein antibody-associated myelitis and subacute combined degeneration

Review Article

Systematic review of novel technology-based interventions for ischemic stroke

Letter to the Editor

Cranial multineuropathy with hypoglossal nerve involvement in a patient with anti-Ku autoantibodies

COVID-19

Latent class cluster analysis identified hidden headache phenotypes in COVID-19: impact of pulmonary infiltration and IL-6

Original Article

Effects of N-Pep-12 dietary supplementation on neurorecovery after ischemic stroke

Book review

Wolfgang Grisold, Riccardo Soffietti, Stefan Oberndorfer, Guido Cavaletti (eds): Effects of cancer treatment on the nervous system